November 2023 in “Indian Dermatology Online Journal” This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.
January 2024 in “Pakistan Journal of Medicine and Dentistry” This case report describes the co-existence of Celiac Disease and Systemic Lupus Erythematosus in an 18-year-old girl, managed with a gluten-free diet, steroids, and hydroxychloroquine.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.
87 citations
,
July 2012 in “Expert Review of Clinical Immunology” This review outlines pregnancy risks in systemic lupus erythematosus and emphasizes that active lupus nephritis at conception increases the risk of flares and poor obstetric outcomes; it reports no new clinical findings.
1 citations
,
May 2025 in “The Journal of Rheumatology” This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.
9 citations
,
April 1986 in “Postgraduate Medicine” This article reviews the causes of hair loss in pediatric and adult populations, emphasizing the importance of distinguishing between primary dermatologic conditions and those related to systemic diseases, but reports no new clinical findings.
6 citations
,
January 2014 in “American Journal of Medical Case Reports” This case report highlights a 17-year-old girl with overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus, emphasizing the critical importance of early diagnosis and intensive therapy including plasma exchange.
May 2025 in “The Journal of Rheumatology” This case report highlights the importance of trans-esophageal echocardiography in distinguishing Libman-Sacks endocarditis from infective endocarditis in systemic lupus erythematosus patients, guiding appropriate treatment for associated cerebrovascular disease.
January 2026 in “Frontiers in Immunology” This case study details a 44-year-old woman with rheumatoid arthritis and systemic lupus erythematosus who developed hypereosinophilic asthma and was initially treated as ANCA-negative eosinophilic granulomatosis with polyangiitis. Her condition, eventually classified as HASM, underscores the need for evaluating EGPA-spectrum disorders in similar scenarios.
March 2025 in “Pediatric Rheumatology” This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.
30 citations
,
September 2005 in “Best Practice & Research Clinical Rheumatology” This review discusses therapies for skin lesions in lupus erythematosus and reports no new clinical results, focusing on defining and managing refractory disease.
9 citations
,
August 2002 in “Current Opinion in Pediatrics” This article discusses the roles of pediatrics and dermatology departments at Yale University School of Medicine, but reports no specific clinical results.
227 citations
,
November 2004 in “Medicine” This study found that late-onset systemic lupus erythematosus in a French cohort was characterized by a lower disease severity but reduced survival mainly attributed to aging-related factors.
January 2024 in “Indian Journal of Paediatric Dermatology” In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.
3 citations
,
October 2013 in “International Journal of Rheumatic Diseases” This case report found that a patient with cutaneous polyarteritis nodosa experienced rare and severe manifestations, including digital gangrene and a breast ulcer, requiring aggressive treatment and resulting in below-knee amputation.
April 2025 in “Journal of Cosmetic Dermatology” In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.
3 citations
,
November 2021 in “Frontiers in medicine” In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.
14 citations
,
January 2017 in “Annals of Dermatology” In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.
8 citations
,
January 2008 in “Annals of Dermatology” This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” In this prospective clinical trial, azathioprine with steroid minipulse therapy and methotrexate with steroid minipulse therapy both improved hair regrowth in alopecia areata patients, but methotrexate showed slightly higher efficacy.
July 2013 in “Our Dermatology Online” In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.
December 2011 in “InTech eBooks” This review discusses the potential role of systemic corticosteroids in the treatment of progressive vitiligo, but reports no new clinical results and suggests further research is needed.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.
May 2025 in “The Journal of Rheumatology” This report describes two cases where female patients with chronic granulomatous disease developed manifestations of systemic lupus erythematosus, highlighting a rare association that may influence clinical evaluation and treatment planning.
December 2023 in “Curēus” In this case study, a 36-year-old female with severe lupus enteritis and intestinal pseudo-obstruction showed significant clinical improvement after treatment with intravenous methylprednisolone, hydroxychloroquine, and cyclophosphamide, highlighting the complexities and challenges in diagnosing and managing atypical lupus manifestations.
40 citations
,
July 2007 in “Dermatologic Therapy” This review discusses the pharmacologic properties, mechanisms, dosing options, and adverse effects of systemic glucocorticosteroids in dermatology, but reports no new findings.
December 2025 in “Cosmoderma” This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.
41 citations
,
September 2018 in “Australasian journal of dermatology” This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.
January 2022 in “Medical research archives” This article reviews the potential role of vitamin D supplementation as an adjunct to alemtuzumab therapy in multiple sclerosis management, noting its possible benefits for autoimmune comorbidities and patient adherence, but reports no new clinical results.